NO20055367L - Kombinasjoner som innbefatter paroksetin og 2-(S)-4-fluor-2-metyl-fenyl)-piperazin-1-karboksylsyer (1-(R)-(3,5-bis-trifluor-2-metyl-fenyl)-etyl]metylamid for behandling av depresjon og/eller angst - Google Patents
Kombinasjoner som innbefatter paroksetin og 2-(S)-4-fluor-2-metyl-fenyl)-piperazin-1-karboksylsyer (1-(R)-(3,5-bis-trifluor-2-metyl-fenyl)-etyl]metylamid for behandling av depresjon og/eller angstInfo
- Publication number
- NO20055367L NO20055367L NO20055367A NO20055367A NO20055367L NO 20055367 L NO20055367 L NO 20055367L NO 20055367 A NO20055367 A NO 20055367A NO 20055367 A NO20055367 A NO 20055367A NO 20055367 L NO20055367 L NO 20055367L
- Authority
- NO
- Norway
- Prior art keywords
- phenyl
- methyl
- combinations
- anxiety
- piperazine
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Forehggende oppfirmelse angår terapeutiske kombinasjoner som irmbefatter paroksetin eller fysiologisk akseptable salter eller solvater derav og 2-(S)-(4-fluor-2-metyIfenyl)-piperazin-l-karboksylsyre [1-(R)- (3,5-bis-trifluormetyl-fenyl)-etyl]-metyl-amid eller fysiologisk akseptable salter eller solvater derav, farmasøytiske sammensetninger som irmeholder nevnte kombinasjoner og deres anvendelse ved behandling av depresjon og/eller angst.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0308968.7A GB0308968D0 (en) | 2003-04-17 | 2003-04-17 | Medicaments |
PCT/EP2004/004126 WO2004091624A1 (en) | 2003-04-17 | 2004-04-16 | Combinations comprising paroxetine and 2- (s) - (4-fluoro-2-methyl-phenyl) -piperazine-1-carboxylic acid [1- (r)- (3,5-bis-trifluoro-2-methyl-phenyl) -ethyl]-methyl amide for treatment of depression and/or anxiety |
Publications (1)
Publication Number | Publication Date |
---|---|
NO20055367L true NO20055367L (no) | 2005-11-14 |
Family
ID=9956996
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20055368A NO20055368L (no) | 2003-04-17 | 2005-11-14 | Kombinasjoner av paroksetin og 4-(S)-(4-acetyl-piperazin-1-yl-)-2-(R)-(4-trifluor-2-metyl-fenyl)-piperidin-1-karboksylsyre{1\\[1-(R)-3,5-bis-trifluormetyl-fenyl)-etyl]metylamid for behandling av depresjon og/eller angst |
NO20055367A NO20055367L (no) | 2003-04-17 | 2005-11-14 | Kombinasjoner som innbefatter paroksetin og 2-(S)-4-fluor-2-metyl-fenyl)-piperazin-1-karboksylsyer (1-(R)-(3,5-bis-trifluor-2-metyl-fenyl)-etyl]metylamid for behandling av depresjon og/eller angst |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20055368A NO20055368L (no) | 2003-04-17 | 2005-11-14 | Kombinasjoner av paroksetin og 4-(S)-(4-acetyl-piperazin-1-yl-)-2-(R)-(4-trifluor-2-metyl-fenyl)-piperidin-1-karboksylsyre{1\\[1-(R)-3,5-bis-trifluormetyl-fenyl)-etyl]metylamid for behandling av depresjon og/eller angst |
Country Status (18)
Country | Link |
---|---|
US (4) | US20060241124A1 (no) |
EP (4) | EP1615641A1 (no) |
JP (4) | JP2006523652A (no) |
KR (2) | KR20060003876A (no) |
CN (2) | CN1809355A (no) |
AU (2) | AU2004229179A1 (no) |
BR (2) | BRPI0409377A (no) |
CA (2) | CA2522313A1 (no) |
CO (1) | CO5700753A2 (no) |
GB (1) | GB0308968D0 (no) |
IS (2) | IS8129A (no) |
MA (2) | MA27731A1 (no) |
MX (2) | MXPA05011064A (no) |
NO (2) | NO20055368L (no) |
PL (2) | PL377858A1 (no) |
RU (2) | RU2005135647A (no) |
WO (4) | WO2004091624A1 (no) |
ZA (2) | ZA200508067B (no) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0203020D0 (en) | 2002-02-08 | 2002-03-27 | Glaxo Group Ltd | Chemical compounds |
GB0403149D0 (en) * | 2004-02-12 | 2004-03-17 | Glaxo Group Ltd | Medicament |
GB0409098D0 (en) * | 2004-04-23 | 2004-05-26 | Glaxo Group Ltd | Medicament |
GB0426942D0 (en) * | 2004-12-08 | 2005-01-12 | Glaxo Group Ltd | Medicament |
WO2007012968A2 (en) * | 2005-07-29 | 2007-02-01 | Aurobindo Pharma Ltd | Stable dosage form of an antidepressant |
GB0621229D0 (en) * | 2006-10-20 | 2006-12-06 | Glaxo Group Ltd | Novel use |
EP2129381A1 (en) | 2007-01-24 | 2009-12-09 | Glaxo Group Limited | Pharmaceutical compositions comprising 3, 5-diamin0-6- (2, 3-dichl0phenyl) -l, 2, 4-triazine or r (-) -2, 4-diamino-5- (2, 3-dichlorophenyl) -6-fluoromethyl pyrimidine and an nk1 |
WO2012175434A1 (en) * | 2011-06-20 | 2012-12-27 | Glaxo Group Limited | Pharmaceutical formulations comprising vestipitant |
CN103446066B (zh) * | 2013-09-16 | 2014-12-24 | 南通丝乡丝绸有限公司 | 帕罗西汀冻干粉针及其制备方法 |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL111002A (en) * | 1993-09-22 | 1998-09-24 | Glaxo Group Ltd | History of piperidine, their preparation and the pharmaceutical preparations containing them |
US6117855A (en) * | 1996-10-07 | 2000-09-12 | Merck Sharp & Dohme Ltd. | Use of a NK-1 receptor antagonist and an antidepressant and/or an anti-anxiety agent |
JP2001523245A (ja) * | 1997-04-24 | 2001-11-20 | メルク シヤープ エンド ドーム リミテツド | 肥満を治療するためのnk−1受容体拮抗薬およびssriの使用 |
GB9923748D0 (en) * | 1999-10-07 | 1999-12-08 | Glaxo Group Ltd | Chemical compounds |
US6436928B1 (en) * | 1999-12-17 | 2002-08-20 | Schering Corporation | Selective neurokinin antagonists |
JP2003522739A (ja) * | 1999-12-17 | 2003-07-29 | シェーリング コーポレイション | 選択的ニューロキニンアンタゴニスト |
GT200100147A (es) * | 2000-07-31 | 2002-06-25 | Derivados de imidazol | |
GB0025354D0 (en) * | 2000-10-17 | 2000-11-29 | Glaxo Group Ltd | Chemical compounds |
GB0119797D0 (en) * | 2001-08-14 | 2001-10-03 | Glaxo Group Ltd | Chemical compounds |
ATE374183T1 (de) * | 2001-11-13 | 2007-10-15 | Schering Corp | Nk1-antagonisten |
GB0203020D0 (en) * | 2002-02-08 | 2002-03-27 | Glaxo Group Ltd | Chemical compounds |
-
2003
- 2003-04-17 GB GBGB0308968.7A patent/GB0308968D0/en not_active Ceased
-
2004
- 2004-04-16 EP EP04739085A patent/EP1615641A1/en not_active Withdrawn
- 2004-04-16 MX MXPA05011064A patent/MXPA05011064A/es unknown
- 2004-04-16 KR KR1020057019521A patent/KR20060003876A/ko not_active Application Discontinuation
- 2004-04-16 US US10/552,869 patent/US20060241124A1/en not_active Abandoned
- 2004-04-16 WO PCT/EP2004/004126 patent/WO2004091624A1/en active Application Filing
- 2004-04-16 CA CA002522313A patent/CA2522313A1/en not_active Abandoned
- 2004-04-16 JP JP2006505188A patent/JP2006523652A/ja active Pending
- 2004-04-16 WO PCT/EP2004/004122 patent/WO2004091616A1/en active Application Filing
- 2004-04-16 BR BRPI0409377-1A patent/BRPI0409377A/pt not_active Application Discontinuation
- 2004-04-16 JP JP2006505187A patent/JP2006523651A/ja active Pending
- 2004-04-16 CN CNA2004800171620A patent/CN1809355A/zh active Pending
- 2004-04-16 PL PL377858A patent/PL377858A1/pl not_active Application Discontinuation
- 2004-04-16 MX MXPA05011063A patent/MXPA05011063A/es unknown
- 2004-04-16 BR BRPI0409379-8A patent/BRPI0409379A/pt not_active Application Discontinuation
- 2004-04-16 PL PL377857A patent/PL377857A1/pl not_active Application Discontinuation
- 2004-04-16 US US10/552,870 patent/US20060241143A1/en not_active Abandoned
- 2004-04-16 JP JP2006505185A patent/JP2006523649A/ja active Pending
- 2004-04-16 WO PCT/EP2004/004124 patent/WO2004091617A1/en active Application Filing
- 2004-04-16 JP JP2006505186A patent/JP2006523650A/ja active Pending
- 2004-04-16 EP EP04727895A patent/EP1613325A1/en not_active Withdrawn
- 2004-04-16 AU AU2004229179A patent/AU2004229179A1/en not_active Abandoned
- 2004-04-16 EP EP04727896A patent/EP1653956A1/en not_active Withdrawn
- 2004-04-16 RU RU2005135647/15A patent/RU2005135647A/ru not_active Application Discontinuation
- 2004-04-16 US US10/552,871 patent/US20060217395A1/en not_active Abandoned
- 2004-04-16 CA CA002522311A patent/CA2522311A1/en not_active Abandoned
- 2004-04-16 RU RU2005135649/15A patent/RU2005135649A/ru not_active Application Discontinuation
- 2004-04-16 EP EP04739086A patent/EP1615642A1/en not_active Withdrawn
- 2004-04-16 AU AU2004229181A patent/AU2004229181A1/en not_active Abandoned
- 2004-04-16 WO PCT/EP2004/004121 patent/WO2004091615A1/en active Application Filing
- 2004-04-16 KR KR1020057019520A patent/KR20060003875A/ko not_active Application Discontinuation
- 2004-04-16 US US10/552,982 patent/US20060287325A1/en not_active Abandoned
- 2004-04-16 CN CNA2004800172252A patent/CN1809359A/zh active Pending
-
2005
- 2005-10-06 ZA ZA200508067A patent/ZA200508067B/en unknown
- 2005-10-06 ZA ZA200508068A patent/ZA200508068B/en unknown
- 2005-10-14 CO CO05105292A patent/CO5700753A2/es not_active Application Discontinuation
- 2005-10-19 MA MA28562A patent/MA27731A1/fr unknown
- 2005-10-19 MA MA28561A patent/MA27730A1/fr unknown
- 2005-11-14 NO NO20055368A patent/NO20055368L/no not_active Application Discontinuation
- 2005-11-14 NO NO20055367A patent/NO20055367L/no not_active Application Discontinuation
- 2005-11-15 IS IS8129A patent/IS8129A/is unknown
- 2005-11-15 IS IS8128A patent/IS8128A/is unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20055367L (no) | Kombinasjoner som innbefatter paroksetin og 2-(S)-4-fluor-2-metyl-fenyl)-piperazin-1-karboksylsyer (1-(R)-(3,5-bis-trifluor-2-metyl-fenyl)-etyl]metylamid for behandling av depresjon og/eller angst | |
NO20050701L (no) | 4-pyrrolidino-fenyl-benzyleter derivater | |
JP2005532372A5 (no) | ||
NO20161634A1 (no) | 3-Z-[1-(4-(N-((4-metyl-piperazin-1-yl)-metylkarbonyl)-N-metyl-amino)-anilino)-1-fenyl-metylen]-6-metoksykarbonyl-2-indolinon, tautomerene, diastereomerene, enantiomerene, blandinger derav og saltene derav, og i kombinasjon med en ytterligere farmakologisk aktiv substans, for anvendelse i forebygging eller behandling av fibrose ved revmatoid artritt | |
NO20081482L (no) | Delta- og epsilon-krystallformer for imatinibmesylat | |
BRPI0416801A (pt) | derivados de 1h-imidazoquinolina como inibidores de proteìna sinase | |
UA100364C2 (xx) | Сукцинат біфеніл-2-ілкарбамінової кислоти 1-$2-(2-хлор-4-{$(r)-2-гідрокси-2-(8-гідроксі-2-оксо-1,2-дигідрохінолін-5-іл)етиламіно]метил]}-5-метоксифенілкарбамоїл)етил]піперидин-4-іл-естеру та його застосування для лікування легеневих розладів | |
EP2319925A3 (en) | Therapeutic uses of inhibitors of RTP801 | |
NO20073059L (no) | 2,3,4,9-tetrahydro-1h-carbazole derivatives as crth2 receptor antagonists | |
ZA200305412B (en) | 4-fluoro-N-indan-2-yl benzamide and its use as pharmaceutical. | |
WO2004019884A3 (en) | Agents and methods for enhancing bone formation | |
NO20060020L (no) | 3-fluorpiperidiner som NMDA/NR2B-antagonister | |
EA200400881A1 (ru) | Азаарилпиперазины | |
NO20082498L (no) | Diarylurea for behandling av pulmonar hypertensjon | |
IL179206A0 (en) | Pyrrolylpyrimidine derivatives and pharmaceutical compositions containing the same | |
TNSN05222A1 (en) | Pharmaceutical composition comprising 5-methyl-2-2'-(chloro-6'-fluoroanilino) phenylacetic acid | |
NO20065835L (no) | Medikamenter som inneholder N-sulfamoyl-N'-arylpiperaziner for profylakse eller behandling av overvekt og beslektede tilstander | |
EP2308837A3 (en) | Derivatives of arylsulfonamido-substituted hydroxamic acid as matrix metalloproteinases inhibitors | |
NO20076405L (no) | Anvendelse av 24-nor-UDCA | |
NO20091969L (no) | N-(2-hydroksyetyl)-N-metyl-4-(quinolin-8-yl(1-(tiazol-4-ylmetyl)piperidin-4-yliden)metyl)benzamid, fremgangsmate for fremstilling av den sa vel som dens anvendelse for behandling av smerte, angst og depresjon | |
NO20050903L (no) | Nye piperazinyl-pyrazinonderivater for behandling av 5HT-2A reseptorrelaterte forstyrrelser | |
NO20060781L (no) | Anvendelse av loselig CD164 ved inflammatoriske og/eller autoimmune lidelser | |
ATE400552T1 (de) | 4,4' -dithiobis- (3-aminobutane-1-sulfonate)- derivate und sie enthaltende zusammensetzungen | |
WO2005070903A3 (en) | Sulphonamide substituted triazines as chemokine receptor modulators | |
JO2724B1 (en) | 3-Alternative-5 -6-Amino Alkyl Indole-2-Carboxyl Acid Amide and Related Isotopes as Casein Kinase Inhibitors |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC2A | Withdrawal, rejection or dismissal of laid open patent application |